Terminal Sterilization Limits and pH Drift in Aqueous Injectable Formulations

Injectable manufacture from Puqingwang Powder begins with solubility screening in water-for-injection at 20–30 °C across pH 3.0–9.0, not with direct dissolution at final batch scale. When the target concentration is 50 mg/mL, batch compounding requires 50.0 g/L active substance plus a moisture-corrected overage of 1%–2%. Solubility failures at neutral pH are handled by pH adjustment with 0.1 N HCl or NaOH and, if necessary, cosolvent addition not exceeding 20% v/v propylene glycol unless toxicological data support a higher limit. The solution is prepared in a 316L stainless-steel jacketed vessel under nitrogen overlay when forced-degradation data show oxidative susceptibility; dissolved oxygen is reduced to <2 ppm before filtration. Pre-filtration bioburden should be ≤10 CFU/100 mL, and endotoxin limits are calculated from the maximum veterinary dose using Ph. Eur. 2.6.14 or USP <85>; for a parenteral product dosed at 1 mg/kg, an endpoint of 0.5 EU/mg is a conservative control limit. Sterilizing-grade filtration through 0.22 µm PES membranes is followed by terminal autoclaving at 121 °C for 15 minutes only if the active substance shows no assay loss greater than 5% and no unknown impurity increase greater than 0.2% after F0 15; if the powder is heat-labile, aseptic filtration and filling under EU GMP Annex 1 are required. Particulate matter in the finished vial must meet USP <788> or Ph. Eur. 2.9.19 limits. Product-specific autoclave stability data for this powder are not published; thermal cycle selection must therefore be justified by pilot-scale F0 mapping rather than by direct transfer of a compendial cycle. Terminal dosage forms include aqueous solutions for subcutaneous, intramuscular, or intravenous administration filled into Type I or Type II glass vials from 50 mL to 250 mL with chlorobutyl rubber stoppers, and, where licensed, large-volume bags for slow infusion.

What Carryover Limits Apply When the Powder Is Diluted as a 5% Premix?

In medicated feed, the API powder is rarely added directly to the mixer. The first manufacturing stage is an intermediate premix at 1%–10% w/w. When a 5% w/w premix is specified, each 20 kg of carrier receives 1 kg of Puqingwang Powder; if that premix is incorporated at 10 kg per tonne into final feed, the complete feed contains 500 mg/kg active substance. This value must be checked against the licensed daily dose, bodyweight, and daily feed intake, not carried across species without recalculation. Regulatory control under Regulation (EU) 2019/4 requires homogeneous distribution and defined carryover; US FDA 21 CFR 558 applies to medicated feed applications. The manufacturing process uses a two-stage geometric dilution: 1:10 with a 150–250 µm lactose or wheat middlings carrier, followed by 1:10 with the remaining carrier in a double-ribbon blender filled to 60–70% of rated volume at 15 rpm for 20 minutes. Homogeneity is tested by collecting 10 samples across top, middle, and bottom zones after discharge; the coefficient of variation should not exceed 5.0% RSD by a validated HPLC method. Terminal products include medicated complete feed, milk replacer powders, and top-dressing mineral mixtures. The main failure mode in production is carrier–API segregation when particle-size span exceeds 200 µm; the premix is therefore re-sieved through 500 µm before final packaging.

Because drinking-water medication requires rapid wetting and dispersion at ambient temperature, water-soluble oral powders made from Puqingwang Powder are formulated with a different carrier system than feed premixes. The dry powder is usually blended to contain 1%–10% w/w active substance, and the end user reconstitutes a stock solution at 50 g/L; subsequent in-line dilution to 0.1–1.0 mg/mL depends on water intake and prescribed dose. The final powder must hydrate within 2–3 minutes in water at 10–20 °C without foaming, caking, or leaving undissolved particles; citric acid and sodium citrate are added to control final pH between 5.5 and 6.5, and silica is used at 0.2%–0.5% w/w as a moisture scavenger when packaging is not fully airtight. Blending is conducted at relative humidity <30% and 20–30 °C in a V-shell or double-cone blender for 15–20 minutes, followed by filling into aluminium foil sachets or HDPE tubs with induction sealing. The applicable standards include Regulation (EU) 2019/6 for the veterinary medicinal product and EU GMP Part I for finished manufacturing; microbial quality should meet Ph. Eur. 5.1.4 limits for non-sterile oral products. Terminal dosage forms are water-soluble powders for oral solution or stock solutions sold in multi-dose sachets and bulk packs.

When Direct Compression Is Not Feasible Because the API Particle Size Falls Below 50 µm

Direct compression of low-dose veterinary tablets fails when the milled API has a median particle size below 50 µm because the cohesive powder does not flow through the press feed frame and causes weight variation outside Ph. Eur. 2.9.40 or USP <905>. In such cases, the API addition in the tableting blend is set between 0.5% w/w and 30% w/w depending on the dose; a low-dose 2% w/w formulation is first preblended 1:5 with microcrystalline cellulose in a high-shear mixer at 100–150 rpm for 3 minutes. The preblend is then dry-granulated on a roller compactor with a roll gap of 2 mm and hydraulic pressure of 8–12 kN/cm, milled through an 800 µm screen, and blended with croscarmellose sodium 2% w/w and magnesium stearate 0.5% w/w for another 5 minutes in a bin blender at 10 rpm. Final moisture should be <2.0% w/w before compression. Tablets are compressed on a 16-station rotary press at 8–18 kN, with target hardness 60–120 N and friability <1.0% per Ph. Eur. 2.9.7. The terminal dosage forms are conventional tablets, scored tablets, and large-animal boluses; if a bolus is required, the same granulation is compressed at 20–40 kN into larger dies. Regulatory controls for content uniformity cite Ph. Eur. 2.9.40 and USP <905>, while dissolution testing follows the registered veterinary monograph. When the API dose exceeds 30% w/w, direct compression becomes impractical because excipient pressure transmission drops and capping frequency increases at press speeds above 30 rpm.

Unlike tablet compression, capsule filling creates vertical segregation inside the hopper, so low-dose blends for Puqingwang Powder are designed with carrier particle-size matching and minimal bulk-density differences. The API addition ratio in capsule fill is typically 1%–25% w/w; a 10% w/w fill requires 10.0 g API per 100 g total powder, adjusted for moisture content. Lactose monohydrate with a particle-size range of 100–180 µm is used as the main diluent, and the API is first preblended 1:3 with lactose for 5 minutes in a low-shear tumble blender at 10 rpm before the remaining diluent and 0.5% w/w magnesium stearate are added and blended for an additional 3–5 minutes. Overlubrication beyond 5 minutes at low shear can reduce powder wettability and dissolution, so mixing time is treated as a controlled parameter. The fill is processed on a dosing-disc or tamping-pin capsule filling machine with fill weight 150–600 mg for size 1–00 capsules. Finished capsules are tested for content uniformity using Ph. Eur. 2.9.40 or USP <905>, and disintegration or dissolution is controlled by the registered veterinary specification. Terminal products include hard gelatin capsules and HPMC capsules packed in blisters or HDPE bottles.

Granule Growth Is Governed by Air Temperature and Binder Viscosity

Fluid-bed granulation of veterinary API powders is selected when dust control and dissolution rate improvement override the simplicity of dry blending. The API is introduced as a solid in the powder bed or dissolved/suspended in the binder solution; for Puqingwang Powder, the preferred route is to blend the API with lactose starting at 1%–15% w/w dry basis and spray a 5% w/w PVP K30 binder solution at 8–12 g/min per kg of bed material. The process is run in a top-spray fluid-bed dryer with inlet air temperature 55–65 °C, product temperature 32–36 °C, air volume 80–120 m³/h for a 5 kg batch, and atomization air pressure 1.0–1.5 bar. Binder viscosity should remain between 5 and 15 mPa·s; above 50 mPa·s droplet size increases and surface crusting occurs before intragranular binding is achieved. After spraying, the granules are dried to final loss on drying <2.0% w/w and sieved through 500 µm. Particle-size distribution is measured per Ph. Eur. 2.9.3 or USP <786>. The terminal forms are granules for direct oral administration, granules for reconstitution, or granules as an intermediate for subsequent tablet or capsule filling. If the API is moisture-sensitive, the inlet temperature is reduced to 50 °C and spray rate is lowered by 20%, but the product temperature should not fall below 30 °C because uneven binder deposition produces friable granules. Published scale-up data for this exact powder in fluid-bed equipment are limited; pilot batches should therefore be used to establish equipment-specific air-flow and spray-rate ranges before commercial scale-up.

When individual animal dosing is required and water medication is impractical, oral drench solutions prepared from Puqingwang Powder are manufactured as aqueous or cosolvent vehicles at active concentrations of 2%–10% w/v. The formula may contain propylene glycol 10%–20% v/v as solubility enhancer and benzyl alcohol 1%–1.5% v/v as preservative; if the API is not fully soluble, xanthan gum 0.2% w/v is hydrated for 60 minutes under high shear to provide suspension stability. The batch is mixed in a 316L stainless-steel vessel at 400–800 rpm and 25–30 °C, pH adjusted to the range established by stability data, and passed through 0.45 µm filtration only for true solutions; suspensions are not filtered through sterilizing membranes. Applicable standards include Regulation (EU) 2019/6 for the veterinary medicinal product and Ph. Eur. 5.1.4 for non-sterile oral preparations. Terminal dosage forms are oral drench solutions or suspensions in 1 L or 5 L multidose HDPE bottles. Stability data for non-aqueous cosolvent systems at 40 °C/75% RH should be generated before pilot scale; published data for this powder in these vehicles are limited, so forced-degradation screening must include pH, cosolvent ratio, and preservative compatibility.